Mersana Therapeutics Inc [MRSN] stock is trading at $1.56, up 10.64%. An important factor to consider is whether the stock is rising or falling in short-term value. The MRSN shares have gain 19.08% over the last week, with a monthly amount drifted -21.21%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mersana Therapeutics Inc [NASDAQ: MRSN] stock has seen the most recent analyst activity on March 19, 2024, when JP Morgan upgraded its rating to a Neutral but kept the price target unchanged to $5 for it. Previously, Wedbush upgraded its rating to Outperform on February 29, 2024, and elevated its price target to $7. On February 29, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $7 on the stock. BTIG Research upgraded its rating to a Buy but stick to its price target of $6 on February 29, 2024. Citigroup upgraded its rating to a Buy and raised its price target to $5 on December 04, 2023. Robert W. Baird downgraded its rating to Neutral for this stock on July 28, 2023, and downed its price target to $1. In a note dated July 27, 2023, Wedbush downgraded an Neutral rating on this stock.
Mersana Therapeutics Inc [MRSN] stock has fluctuated between $1.07 and $6.28 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Mersana Therapeutics Inc [NASDAQ: MRSN] shares were valued at $1.56 at the most recent close of the market. An investor can expect a potential return of 92.31% based on the average MRSN price forecast.
Analyzing the MRSN fundamentals
Mersana Therapeutics Inc [NASDAQ:MRSN] reported sales of 29.94M for the trailing twelve months, which represents a drop of -78.48%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -3.6%, Pretax Profit Margin comes in at -3.5%, and Net Profit Margin reading is -3.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -3.34 and Total Capital is -0.92. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4467 points at the first support level, and at 1.3333 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6267, and for the 2nd resistance point, it is at 1.6933.
Ratios To Look Out For
For context, Mersana Therapeutics Inc’s Current Ratio is 2.72. On the other hand, the Quick Ratio is 2.72, and the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 6.39, the price to book ratio is 22.71.
Transactions by insiders
Recent insider trading involved Protopapas Anna, Director, that happened on Jan 16 ’24 when 29399.0 shares were sold. SVP, Chief Manuf. Officer, MISRA TUSHAR completed a deal on Jan 16 ’24 to sell 3357.0 shares. Meanwhile, VP, Chief Accounting Officer Mandelia Ashish sold 5025.0 shares on Jan 16 ’24.
